High-quality evidences showed that for patients with DCM, atorvastatin could significantly improve LVEF and reduce CRP; carvedilol also could significantly improve LVEF and reduce SBP, LVEDV, and LVESV; at the same time, thyroid hormone could also significantly improve LVEF and cardiac output and reduce LVEDD; L-carnitine also could markedly reduce LVEDD; furthermore, ICD therapy could significantly reduce sudden cardiac death. This evidence concerns the gene CRP and familial dilated cardiomyopathy.